Early and late microvascular obstruction (MO) assessed by magnetic resonance imaging (MRI) are prognostic markers for combined clinical endpoints after ST-elevation myocardial infarction (STEMI). However, there are only limited data for hard endpoints and no consensus exists which of the two best predicts clinical outcome. Furthermore, it is unclear whether the assessment of MO by MRI adds incremental prognostic information independent of traditional outcome markers.
Microvascular obstruction in contrast-enhanced MRI can be assessed by different techniques and different time points such as by early imaging usually within the first minute after gadolinium injection and late imaging 15 min after contrast injection. The presence of both early and late MO has been shown to be associated with adverse remodelling in the reperfused STEMI. 6 -10 In addition, in a limited number of patients the presence of MO was associated with worse short-and mid-term prognosis for combined clinical endpoints, including unstable angina, re-hospitalization, and repeat revascularization. 9, 10 However, the extent of MO on clinical outcome has not been evaluated yet. Currently, no consensus exists as to which of the techniques is more accurate and best predicts the clinical outcome. Furthermore, it is unclear whether the assessment of MO by MRI adds incremental prognostic information above more easily assessed angiographic and electrocardiographic parameters or clinical risk stratification tools, such as the thrombolysis in myocardial infarction (TIMI)-flow, 11, 12 ST-segment resolution 13 , or the TIMI-risk score.
14 Aim of the current trial was therefore to compare the impact of the presence and also the extent of early and late MO on longterm prognosis for hard clinical endpoints in a large prospective study cohort and to assess the additional prognostic value in the setting of traditional clinical risk stratification.
Methods Patients and study design
From February 2006 to July 2008, 512 consecutive STEMI patients underwent primary percutaneous coronary intervention (PCI) at our tertiary care centre. Of these, 438 patients underwent cardiac MRI during the index hospitalization. Inclusion criteria were the presence of symptoms ,12 h and ST-segment elevation of at least 0.1 mV in ≥2 extremity leads or at least 0.2 mV in ≥2 precordial leads. Exclusion criteria for the current analysis were prior fibrinolysis and contraindications to MRI at study entry.
All patients underwent detailed assessment of medical history as well as physical examination at the index hospitalization. Hypertension, hyperlipoproteinaemia, diabetes, and smoking were assessed using previous definitions. 15 The TIMI-risk score was calculated for all patients. 14 All patients received 500 mg of aspirin and heparin (60 U/kg bodyweight) intravenously prior to PCI. Clopidogrel with a 600 mg loading dose and subsequently 75 mg for 12 months plus aspirin indefinitely was mandatory. Glycoprotein IIb/IIIa inhibitors, angiotensin-converting enzyme inhibitors or angiotensin-II-receptor antagonists, beta-blockers, and statins were administered according to the current guidelines. 16, 17 Follow-up was conducted via telephone contact using a standard questionnaire. In case of any event, these were verified by hospital charts, direct contact with the treating physician, or contact with the local government registration. The follow-up interviewer was not aware of the results of the MRI studies. The study was approved by the local ethics committee and all patients gave written informed consent.
Primary percutaneous coronary intervention and angiographic analysis
Primary PCI was performed according to standard clinical practice. The decision whether to use bare-metal or drug-eluting stents was left at the discretion of the interventional cardiologist. Additional thrombectomy was used depending on thrombus burden in the infarct-related artery.
Coronary angiography of the target lesion was performed before and after PCI with the same projections. Angiographic projections used were those allowing optimal evaluation of the TIMI-flow of the infarct-related artery. 12 An angiographic visual analysis was performed offline in the angiographic core laboratory by two independent observers blinded to clinical events and MRI results. Patients were grouped according to post-TIMI flows: TIMI-flow III (reperfusion success) and TIMI-flow 0-II (incomplete reperfusion or lack of procedural success).
ST-segment resolution
Early ST-segment resolution was evaluated by measuring the sum of ST-segment elevation 20 ms after the end of the QRS complex in the ECG before and after PCI. The percentage resolution of ST-segment elevation from before to after PCI was calculated as described previously. 13, 18 Patients were divided into three groups according to the degree of ST-segment resolution: complete (≥70%), partial (30 -70%), and none (,30%). 13 
Magnetic resonance imaging
Imaging was performed on a 1.5 Tesla scanner (Philips Intera CV, Best, The Netherlands). The scan protocol and technical parameters have been described previously and are displayed in Figure 1 .
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All measurements were performed offline using dedicated software (ViewForum release 5.2; Philips Medical Systems, Best, The Netherlands) by operators blinded to clinical, angiographic, and electrocardiographic parameters at the MRI core laboratory, which has proved excellent reproducibility as well as inter-and intra-observer variabilities. 19 For acute infarct determination, three short-axis slices using a T2-weighted turbo spin-echo sequence were obtained before contrast agent administration. Left ventricular (LV) ejection fraction (EF) and end-diastolic, end-systolic volumes were calculated from the short-axis views. The corresponding EF was graded as severely decreased (,35%), mildly to moderately decreased (35-55%), and normal (.55%).
Total LV mass and infarct size, expressed as a percentage of LV mass (%LV), were assessed manually as described previously. 18, 19 Microvascular obstruction was assessed 1 and 15 min after gadolinium injection (early and late MO, Figure 2 ) by an inversion recovery gradient echo technique and was determined similarly by manual drawing of the obstructed area within the infarction of the short-axis slices and expressed as %LV. For further analysis, all patients were grouped according to the corresponding tertiles of the extent of MO.
Endpoints and definitions
The primary endpoint was a composite of death, non-fatal myocardial re-infarction, and congestive heart failure [major adverse cardiovascular events (MACE)]. Secondary endpoints were the individual endpoints of the component. The diagnosis of re-infarction during the index hospitalization was based on clinical symptoms, new ST-segment changes, and an increase in the creatine kinase-MB levels above the reference limits in patients with normalized values or if there was an increase of .20% from the last non-normalized measurement. At follow-up, any new ischaemic symptoms leading to hospital admission accompanied by elevated troponin was defined as recurrent myocardial infarction. New heart failure was defined as any congestive heart failure (rales, dyspnoea New York Heart Association class III -IV) requiring medical attention occurring .24 h after the index event.
When a patient experienced .1 event, the first event was chosen for the combined clinical endpoint. When ≥2 events occurred simultaneously, the most severe event was chosen (death . myocardial re-infarction . congestive heart failure). Between the index event and MRI image acquisition, no events were recorded, with the exception of death in 18 patients, who were consequently excluded from further analysis ( Figure 3 ).
Outcomes were adjudicated by a clinical events committee unaware of the MRI results. clinical endpoint and mortality in relation to the presence of early and late MO. To define the impact of the extent of MO on outcome, KaplanMeier curves were also generated for tertiles of late MO. The incremental prognostic value regarding the composite primary endpoint of a model including the presence and extent of late MO in addition to established prognostic markers compared with a model including only traditional prognostic factors was tested by calculating the respective c-statistics. The method of Pencina et al. was used. 20 The differences in c-statistics were estimated with the method described by Antolini et al. 21 The Hosmer -Lemeshow statistic was used to assess the goodness-of-fit of the applied models. All statistical tests were performed with SPSS software, version 17.0. All probability values were two-tailed with a ¼ 0.05 and all confidence intervals (CI) were calculated to the 95th percentile.
Statistical analysis

Results
Of 512 patients undergoing primary PCI for STEMI, cardiac MRI was conducted in 438 patients during the index hospitalization. The median time between the index event and MRI was 3 days (IQR 2;4). Patient follow-up was performed at a median of 19 months (IQR 11;27) after index infarction and was completed for 97% of patients ( Figure 3 ). In total, MO was present in 332 (78%) patients and absent in 90 (22%) patients, respectively. Baseline characteristics of patients with and without MO are displayed in Table 1 . Among patients with MO, early MO was detected in all 332 patients and late MO in 296 (90%). The extent of early MO compared with the extent of late MO was significantly greater [early MO 2.0% LV (IQR 0.4;5.0), late MO 0.7% LV (IQR 0;1.9), P , 0.001].
Clinical outcome during follow-up
All clinical events occurred in patients with detection of both early and late MO, whereas patients with transient MO (early MO without late MO) remained event-free throughout the follow-up period. 
Prognostic evaluation
In contrast to patients with early MO, Kaplan-Meier estimates illustrated reduced periods of MACE and mortality in patients with late MO compared with patients without MO ( Figure 4A and B). Similar results were observed for the extent of late MO as defined by MO tertiles ( Figure 4C and D) . An univariable survival analysis of MACE and mortality is presented in Table 2 . In comparison with the presence and extent of early MO, post-PCI TIMI-flow, ST-segment resolution, TIMI-risk score, infarct size, LV-EF, the presence of late MO demonstrated the strongest univariable associations with both MACE and mortality (HR 3.60, 95% CI 1.72-7.52, P ¼ 0.001 and HR 5.45, 95% CI 1.28-23.11, P ¼ 0.02, respectively).
In multivariable Cox regression analyses adjusted for post-PCI TIMI-flow, ST-segment resolution, TIMI-risk score, infarct size, and LV-EF, both the presence and extent of late MO were significantly associated with the occurrence of the composite endpoint, whereas this was not the case for the presence or extent of early MO (Tables 3 and 4) . Among all prognostic factors, the presence and extent of late MO were identified as the strongest predictors for MACE and mortality ( Table 3) .
Comparison of a model including only post-PCI TIMI-flow, ST-segment resolution, TIMI-risk score, LV-EF, and infarct size to a model including the presence of late MO in addition to post-PCI TIMI-flow, ST-segment resolution, TIMI-risk score, LV-EF, and infarct size resulted in significant increases of the c-statistics from 0.75 to 0.78 (P , 0.001), thus demonstrating the incremental prognostic value of late MO ( Table 5) .
Discussion
To the best of our knowledge, this is the largest prospective trial to compare the impact of the presence and also the extent of early and late MO assessed by MRI on hard clinical endpoints. The main findings can be summarized as follows: (i) in contrast to early MO, late MO was independently associated with mortality and the occurrence of the combination of death, myocardial re-infarction, and congestive heart failure; (ii) the extent of late MO showed a graded relationship with the occurrence of this composite endpoint; (iii) in the setting of traditional prognostic markers late MO was identified as a strong independent predictor, adding important information on long-term prognosis after STEMI reperfused by primary PCI. . .... ..... ..... ..... .... ..... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ... 9, 10 In both studies, .60% of all events were not attributed to hard endpoints such as death, myocardial re-infarction, and congestive heart failure because re-admission for unstable angina or repeat revascularization were included in the combined clinical endpoint. 9, 10 The current analysis could confirm the prognostic value in a much larger study cohort and most importantly outlines the association of late MO with hard clinical endpoints and mortality independent of traditional prognostic markers. In addition, different methods for the assessment of MO in MRI are currently being used: early (performed by first pass perfusion or inversion recovery gradient echo techniques) in the first minute or late imaging 15 min after contrast injection. 7, 9, 10 Although both methods indicate the same pathophysiological phenomenon, there is no consensus as to which method best predicts the clinical outcome as their relative predictive values have not been directly compared.
Owing to diffusion processes and collateral blood flow, the presence and extent of MO diminish between early and late imaging. 22 Thus, late MO might reflect regions of 'true' no-reflow in contrast to early MO, which represents areas with minimal residual blood flow. Although MO on early imaging may be considered to be more sensitive for the detection of small or less impaired areas of microvascular injury, 23, 24 late MO reflects areas of a more severely disturbed microcirculation that probably accounts for the strong association of late MO with adverse clinical outcome and mortality. This interpretation is supported by the present study: none of the patients displaying transient MO experienced a clinical event.
In addition to the simple presence or absence of MO, our trial showed a graded relationship between the extent of late MO and the occurrence of death, myocardial re-infarction, and congestive heart failure. Moreover, our study demonstrates that even in the presence of traditional prognostic post-infarction scores and parameters, late MO remains a strong independent marker for the long-term outcome after STEMI. The exact mechanisms whereby MO determines postinfarction prognosis remain unknown. One potential explanation is the relationship between the presence of MO and infarct size. 12, 25 Interestingly, infarct size, although predictive in the univariable analysis, did not remain significant in the multivariable model including MO and established prognostic markers and scores, which has been observed previously. 9 Theoretically, early obstruction of microvessels after reperfusion could result in altered local tissue properties relative to regions receiving adequate reperfusion. This concept is supported by previous studies that related the presence of MO to LV remodelling in the post-infarction period. 7, 9, 10 In line with our results on outcome, a previous trial has identified late MO to be a more powerful predictor of functional recovery than ST-segment resolution, TIMI-flow, and blush grade. 7 It is important to mention that data on the incidence of MO in reperfused infarction are not consistent, ranging from 30 to 70% in previous studies. 6, 7, 9, 10, 26, 27 These differences might be explained by differences in study groups and the imaging time after the index event and after contrast injection. 22, 27 In the current study, imaging was performed earlier after the index event than in many previous studies. Imaging time after reperfusion is an important determinant for the presence of MO, which explains in part the relatively high MO presence in our study. 3, 27 Our findings may become relevant in the clinical setting for selecting patients who may benefit from adjunctive therapy to promote the repair of infarcted myocardium and for the intensification of medical or device therapy.
Some limitations of the current trial need to be addressed. First, the number of patients is still limited to draw definitive conclusions on clinical outcome. Second, all patients were treated at a single high-volume tertiary referral centre. As a consequence, the results may not be generalized to the entire STEMI population. Third, the influences of several angiographic and clinical variables that were not available and might have affected outcome were not examined, such as collateral blood flow, myocardial blush grade, and preconditioning. However, angina onset and recurrence is generally subjective and difficult to assess. In addition, appropriate images for the assessment of myocardial blush were not routinely acquired. Finally, no conclusion can be drawn about the prognostic value of MRI compared with other imaging or diagnostic techniques for risk stratification, such as contrast echocardiography or scintigraphic methods.
In conclusion, the presence and extent of late MO assessed by MRI are strong independent predictors for the long-term occurrence of death, myocardial re-infarction, and congestive heart failure, even when compared with traditional post-infarction risk stratification markers and scores. The assessment of MO adds prognostic information and should therefore be considered for further risk stratification.
